Skip to main content
. Author manuscript; available in PMC: 2020 Jul 4.
Published before final editing as: J Neurosurg. 2019 Jan 4:1–12. doi: 10.3171/2018.7.JNS181175

TABLE 1.

Patient characteristics and outcomes

Variable Value
No. of patients 1622
Age in yrs, mean (SD) 52.9 (15.8)
 Range (18–89)
Sex
 Male 769 (47.4)
 Female 853 (52.6)
BMI in kg/m2 28.9 (6.2)
 Range (14.6–59.8)
History of VTE 50 (3.1)
KPS score <80 281 (17.3)
Preop motor deficit 212 (13.1)
Chronic steroid use 544 (33.5)
Preop antiplatelet use 336 (20.7)
Preop anticoagulation 64 (3.9)
Admission type
 Elective 1502 (92.6)
 Nonelective 120 (7.4)
Revision craniotomy 317 (19.5)
Location
 Supratentorial 1362 (84.0)
 Infratentorial 260 (16.0)
 Intraaxial 963 (59.4)
 Extraaxial 659 (40.6)
Pathology
 Glial-based tumor 784 (48.3)
 Schwannoma/meningioma 570 (35.1)
 Metastatic lesion 108 (6.7)
 Other 160 (9.9)
Pathological grade*
 1 568 (35.5)
 2 270 (16.9)
 3 247 (15.4)
 4 516 (32.2)
New postop motor deficit 165 (10.1)
Inpatient extremity ultrasound 137 (8.4)
VTE 48 (3.0)
 Inpatient VTE 20 (1.2)
 Outpatient VTE 28 (1.7)
 DVT 38 (2.3)
 PE 14 (0.9)
 DVT & PE 4 (0.2)
Day of VTE diagnosis 13.1 (9.5)
 Inpatient VTE 5.4 (4.3)
  Range (0–18)
 Outpatient VTE 18.6 (8.3)
  Range (6–30)
Prophylactic anticoagulation 192 (11.8)
 Subcutaneous heparin 77 (40.1)
 Subcutaneous LMWH 110 (57.3)
 Oral anticoagulant 5 (2.6)
Day of chemoprophylaxis initiation 4.6 (3.8)
 Range (0–22)
Postop ICH 30 (1.9)
 ICH after DVT chemoprophylaxis 1 (0.5)
Intubated >24 hr/reintubated 58 (3.6)
Mean LOS in days 3.8 (4.5)
 Range (1–119)
Discharge location
 Home 1298 (80.0)
 Inpatient rehabilitation 240 (14.8)
 Skilled nursing facility 82 (5.1)
 Inpatient mortality 2 (0.1)

LOS = length of stay.

Values are presented as number of patients (%) unless otherwise indicated.

*

There were 21 lesions that were not assigned a pathological grade.

Denominator for percentage was number of patients receiving VTE chemoprophylaxis.